This is a working overview of DPP-4 resistance, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-25. Anything still debated is marked as such rather than presented as settled.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Modelled after Umkhonto we Sizwe, the armed wing of the African National Congress, the South West African Liberation Army (SWALA) was formed by SWAPO in 1962. The first seven SWALA recruits were sent from Dar es Salaam to Egypt and the Soviet Union, where they received military instruction. Upon their return, they began training guerrillas at a makeshift camp established for housing South West African refugees in Kongwa, Tanzania.
Many drugs exist in the treatment of ADHD. Dextroamphetamine (Dexedrine, Dextrostat), Adderall, methylphenidate (Ritalin, Metadate, Concerta, Daytrana), and lisdexamfetamine (Vyvanse) block reabsorption of the catecholamines dopamine and norepinephrine through monoamine transporters (including NET), thereby increasing levels of these neurotransmitters in the brain. The strong selective norepinephrine reuptake inhibitor (NRI), atomoxetine (Strattera), has been approved by the U.S. Food and Drug Administration (FDA) to treat ADHD in adults. The role of the NET in ADHD is similar to how it works to ease the symptoms of depression. The NET is blockaded by atomoxetine and increases NE levels in the brain. It can work to increase one's ability to focus, decrease any impulsiveness, and lessen hyperactivity in both children and adults with ADHD.
=== Australian National University === In the original design of the city of Canberra, the architect, Walter Burley Griffin, had provided for a university and had set aside land for it at the base of Black Mountain, where it would ultimately be built. Sir David Rivett chaired a committee constituted to investigate the proposed medical research institute, how much it would cost, and how it would affect existing and proposed institutions. Florey mailed Rivett a 19-page proposal on 7 April 1945. Florey envisaged a funding body in Australia similar to the Medical Research Council in the UK. The institute would be headed by a director, and have about one hundred staff, which he calculated would cost about £100,000 (equivalent to £3,732,000 in 2025). His estimate of the cost of the building was too low; Florey estimated that £240,000 (equivalent to £8,956,000 in 2025) would be enough for a building for 60 researchers, but it would eventually cost almost four times as much.
Sources: en.wikipedia.org
== Medical uses == Medications based on incretins are used in the treatment of type 2 diabetes mellitus as well as the management of obesity. Most of the earliest incretin-targeting agents to be approved fell into the class of DPP-4 inhibitors; these inhibit DPP-4 and prevent the enzymatic degradation of GLP-1 and GIP. The first medication in this class, sitagliptin, received FDA approval in 2006 for the treatment of type 2 diabetes. GLP-1 analogs principally act as agonists of the GLP-1 receptor and are thus insulinotropic. Exenatide was the first drug in this class to be used in the treatment of type 2 diabetes; it received FDA approval in 2005. More recently, longer-acting and more potent GLP-1 analogs have been developed, most notably semaglutide, which received FDA approval for type 2 diabetes in 2017. It was subsequently approved for the management of obesity. In 2021, it was in the Top 100 most-prescribed drugs in the United States. Tirzepatide (sold as Mounjaro and Zepbound) is a potent GIP analog with agonist activity at GIP and GLP-1 receptors. It was approved for the treatment of type 2 diabetes in the United States in May 2022, and for the management of obesity in November 2023.
However, by 2025, relations had worsened, with US vice president JD Vance in February scolding "flimsy suspicions" and "enormous pressure from its continental neighbours" for causing the annulment of the 2024 Romanian presidential election in which Călin Georgescu won the first round. Relations with Moldova are a special case given that the two countries share the same language and a common history. A movement for unification of Moldova and Romania appeared in the early 1990s after both countries achieved emancipation from communist rule but lost ground in the mid-1990s when a new Moldovan government pursued an agenda towards preserving a Moldovan republic independent of Romania. After the 2009 protests in Moldova and the subsequent removal of Communists from power, relations between the two countries have improved considerably.
February 15: Law amending the decree of July 29, 1939, on family and French natality. March 29: Law creating a single wage allowance (ASU). April 2: Law on divorce and legal separation. September 2: Law on birth protection. September 14: Law concerning sentence adjustments. 1942
A&W is a fast-food restaurant chain in Canada, franchised by A&W Food Services of Canada Inc. The company was initially a subsidiary of the U.S.-based A&W Restaurants chain, with the subsidiary opening its first franchise in Winnipeg in 1956. In 1972, Unilever acquired A&W's Canadian operations, leading to the subsidiary's separation from the U.S.-based company. In 1995, a Canadian management group made up of A&W franchisees took ownership of the chain from Unilever. A&W Food Services of Canada Inc. is a publicly traded company headquartered in North Vancouver. As of 2022, A&W was Canada's second-largest fast-food hamburger chain, with 1,029 franchises, after McDonald's.
Sources: en.wikipedia.org
In 2016, Little was narrowly elected to the Minnesota Senate, defeating Republican Tim Pitcher by 387 votes. He served on the Jobs and Economic Growth Finance and Policy, Transportation Finance and Policy, and Veterans and Military Affairs Finance and Policy committees. While in the Senate, Little was involved in efforts to address the rising cost of insulin. In December 2018, he convened an informal discussion at the state Capitol with patients, advocates, and lawmakers about insulin prices and said he had drafted several proposals aimed at controlling costs, including a price cap. By January 2019, MPR News described Little as a leading Senate advocate for several proposals intended to reduce insulin costs. An insulin-assistance provision passed both legislative chambers that spring but was omitted from the final health and human services budget agreement; Little subsequently convened bipartisan negotiations over an emergency assistance program. The Legislature ultimately passed the Alec Smith Insulin Affordability Act in 2020. Little gained national attention in 2020 for his use of the social media app TikTok. By August, the Star Tribune reported that he had accumulated more than 130,000 followers, and Politico profiled him as one of a small number of elected officials making extensive use of the platform to reach younger voters. Little ran for reelection in 2020 but lost to Republican nominee Zach Duckworth. The contest drew substantial outside spending from both parties.
Wheeler was awarded the Lab on a Chip Pioneers in Miniaturization Award (2017), an E.W.R. Steacie Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC) (2015), a Connaught Foundation McLean Fellowship (2014), the Joseph Black Award from the Royal Society of Chemistry (2012), the Arthur F. Findeis Award from the American Chemical Society (2012), the Young Innovator Award in Analytical Chemistry (2011), and a Sloan Research Fellowship (2009). In January 2024, Wheeler was honored with the Ricardo Aroca Award, recognizing his contributions to analytical chemistry and advancing lab-on-a-chip techniques, particularly through the use of digital microfluidics (DMF), which enables precise manipulation of liquid droplets on electrode arrays. The Award is bestowed upon a scientist living in Canada who has made a notable contribution to the discipline of analytical chemistry while conducting research within the country.
There are no widely accepted functions for the resulting truncated RNA transcripts. However, a study in 1981 found evidence that there was a relationship between the number of abortive transcripts produced and the time until long RNA strands are successfully produced. When RNA polymerase undergoes abortive transcription in the presence of ATP, UTP, and GTP, a complex is formed that has a much lower capacity for abortive recycling and a much higher rate of synthesis of the full-length RNA transcript. A study in 2010 found evidence that these truncated transcripts inhibit termination of RNA synthesis by a RNA hairpin-dependent intrinsic terminator. Oligonucleotide Eukaryotic transcription Bacterial transcription
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.